Literature DB >> 11571638

FLRG, an activin-binding protein, is a new target of TGFbeta transcription activation through Smad proteins.

L Bartholin1, V Maguer-Satta, S Hayette, S Martel, M Gadoux, S Bertrand, L Corbo, C Lamadon, A M Morera, J P Magaud, R Rimokh.   

Abstract

The FLRG gene encodes a secreted glycoprotein that binds to activin and is highly homologous to follistatin, an activin ligand. We cloned the promoter region of the human FLRG gene, and defined the minimal region necessary for transcription activation in a reporter-system assay. We showed that the fragment between positions -130 and +6, which consists of multiple consensus Sp1-binding sites, is required for the constitutive expression of the FLRG gene. We demonstrate here that FLRG mRNA expression is rapidly induced by TGFbeta or by transfection with Smad protein expression vectors in human HepG2 cells. We investigated the transcription-regulation mechanism of FLRG expression in HepG2 cells following treatment with TGFbeta. By deletion and point-mutation analysis of the FLRG promoter, we identified a Smad-binding element involved in the TGFbeta-inducible expression of the FLRG gene. Moreover, transactivation of the FLRG promoter by TGFbeta was compromised by dominant-negative mutants of Smad3 and Smad4 proteins. In addition, gel electrophoresis mobility-shift assays demonstrated the specific interaction of Smad3 and Smad4 proteins with the Smad-binding element consensus motif found in the FLRG promoter. Taken together, our data imply that Smad proteins participate in the regulation of expression of FLRG, a new target of TGFbeta transcription activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571638     DOI: 10.1038/sj.onc.1204720

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  The role of activin in mammary gland development and oncogenesis.

Authors:  Karen A Dunphy; Alan L Schneyer; Mary J Hagen; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-08       Impact factor: 2.673

2.  The Local Control of the Pituitary by Activin Signaling and Modulation.

Authors:  Louise M Bilezikjian; Wylie W Vale
Journal:  Open Neuroendocrinol J       Date:  2011-01-01

Review 3.  Cell-type specific modulation of pituitary cells by activin, inhibin and follistatin.

Authors:  Louise M Bilezikjian; Nicholas J Justice; Alissa N Blackler; Ezra Wiater; Wylie W Vale
Journal:  Mol Cell Endocrinol       Date:  2012-02-04       Impact factor: 4.102

4.  Human placenta and fetal membranes express follistatin-related gene mRNA and protein.

Authors:  P Ciarmela; P Florio; P Toti; A Franchini; V Maguer-Satta; C Ginanneschi; E Ottaviani; F Petraglia
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

5.  Hypoxia enhances the expression of follistatin-like 3 in term human trophoblasts.

Authors:  T Biron-Shental; W T Schaiff; E Rimon; T L Shim; D M Nelson; Y Sadovsky
Journal:  Placenta       Date:  2007-10-23       Impact factor: 3.481

6.  Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1.

Authors:  Brian M Necela; Weidong Su; E Aubrey Thompson
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

7.  Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes.

Authors:  Kalyani D Panse; Leanne E Felkin; Marina M López-Olañeta; Jesús Gómez-Salinero; María Villalba; Lucía Muñoz; Kazuto Nakamura; Masayuki Shimano; Kenneth Walsh; Paul J R Barton; Nadia Rosenthal; Enrique Lara-Pezzi
Journal:  J Cardiovasc Transl Res       Date:  2012-08-23       Impact factor: 4.132

8.  Activin type II receptor signaling in cardiac aging and heart failure.

Authors:  Jason D Roh; Ryan Hobson; Vinita Chaudhari; Pablo Quintero; Ashish Yeri; Mark Benson; Chunyang Xiao; Daniel Zlotoff; Vassilios Bezzerides; Nicholas Houstis; Colin Platt; Federico Damilano; Brian R Lindman; Sammy Elmariah; Michael Biersmith; Se-Jin Lee; Christine E Seidman; Jonathan G Seidman; Robert E Gerszten; Estelle Lach-Trifilieff; David J Glass; Anthony Rosenzweig
Journal:  Sci Transl Med       Date:  2019-03-06       Impact factor: 17.956

9.  The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients.

Authors:  Megan McAleavy; Qian Zhang; Peter J Ehmann; Jianing Xu; Matthew F Wipperman; Dharani Ajithdoss; Li Pan; Matthew Wakai; Raphael Simonson; Abhilash Gadi; Adelekan Oyejide; Sara C Hamon; Anita Boyapati; Lori G Morton; Tea Shavlakadze; Christos A Kyratsous; David J Glass
Journal:  Mol Cell Biol       Date:  2021-11-01       Impact factor: 4.272

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.